By Katherine Hamilton
Omnicell shares fell after the company lowered its guidance due to expected costs and uncertainty from tariffs.
The stock slid 15% to $26.01 on Tuesday morning, at one point touching a 52-week low of $22.66. Shares have lost roughly 43% of their value this year.
The healthcare-technology company, which automates medication management for hospitals and pharmacies, on Tuesday reduced its full-year guidance to account for higher supply-chain costs from tariffs.
Omnicell is now expecting $1.00 to $1.65 in adjusted earnings per share for all of 2025, down from prior guidance of $1.65 to $1.85. Revenue guidance was unchanged.
Chief Executive Randall Lipps said the company is implementing strategies to mitigate potential tariff-related costs, but that uncertainty about those impacts compelled management to lower guidance.
In the first quarter, Omnicell narrowed its loss to $7 million, or 15 cents a share, from its prior-year loss of $15.7 million, or 34 cents a share. Adjusted earnings were 26 cents a share, ahead of the 20 cents a share forecast by Wall Street.
Revenue in the first quarter rose 10% to $269.7 million, ahead of the $259.9 million expected by analysts, according to FactSet.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
May 06, 2025 10:25 ET (14:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。